MAPK Signaling
Research Areas
Products Related to MAPK Signaling(660)
- GC60393(-)-Zuonin ACAS: 84709-25-1Purity: >99.50%
(-)-Zuonin A (D-Epigalbacin), a naturally occurring lignin, is a potent, selective JNKs inhibitor, with IC50s of 1.7 μM, 2.9 μM and 1.74 μM for JNK1, JNK2 and JNK3, respectively.
- GC60812ASTX029 (ERK1/2 inhibitor 2)CAS: 2095719-92-7Purity: >99.50%
ASTX029 (ERK1/2 inhibitor 2) is a highly effective and selective orally bioavailable extracellular signal-regulated kinase (ERK) 1/2 inhibitor (with an IC 50 of 2.7nM for ERK2).
- GC61454GW806742X hydrochloridePurity: >98.50%
GW806742X hydrochloride, an ATP mimetic and a potent MLKL (Mixed Lineage Kinase Domain-Like protein) inhibitor, binds the MLKL pseudokinase domain with a Kd of 9.3 μM. GW806742X hydrochloride has activity against VEGFR2 (IC50=2 nM). GW806742X hydrochloride retards MLKL membrane translocation and inhibits necroptosis.
- GC61466DMU-212CAS: 134029-62-2Purity: >99.50%
DMU-212 is a methylated derivative of Resveratrol, with antimitotic, anti-proliferative, antioxidant and apoptosis promoting activities. DMU-212 induces mitotic arrest via induction of apoptosis and activation of ERK1/2 protein. DMU-212 has orally active.
- GC61485Raf inhibitor 2CAS: 220904-99-4Purity: >98.00%
Raf inhibitor 2 is a potent raf kinase (IC50<1.0 μM) inhibitor, compound 32, extracted from patent EP1003721B1. Raf inhibitor 2 can be used for cancer research.
- GC61512PKA Inhibitor Fragment (6-22) amide TFAPurity: >98.00%
PKA inhibitor fragment (6-22) amide TFA is a synthetic peptide inhibitor of cAMP-dependent protein kinase A (PKA) with K i =1.7 nM.
- GC61765(+)-IsomenthoneCAS: 1196-31-2
(+)-Isomenthone is an isomer of L-Menthone, isolated from Ziziphora clinopodioidesLam. and possesses antioxidant activity.
- GC61849PKI 14-22 amide,myristoylated TFAPurity: >99.50%
PKI 14-22 amide,myristoylated TFA is a potent cAMP-dependent PKA inhibitor. PKI 14-22 amide,myristoylated TFA reduces the IgG-mediated phagocytic response and also inhibits neutrophil adhesion.
- GC62146XST-14CAS: 2607143-50-8Purity: >99.50%
XST-14 is a potent, competitive and highly selective ULK1 inhibitor with an IC50 of 26.6 nM. XST-14 induces autophagy inhibition by reducing the phosphorylation of the ULK1 downstream substrate. XST-14 induces apoptosis in hepatocellular carcinoma (HCC) cells and has antitumor effects.
- GC62206PLX-4720-d7CAS: 1304096-50-1Purity: >98%
PLX-4720-d7 is the deuterium labeled PLX-4720. PLX-4720 is a potent and selective inhibitor of?B-RafV600E?with?an IC50?of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), and 10-fold selectivity for B-RafV600E than wild-type B-Raf.
- GC62315MKK7-COV-9CAS: 2283355-59-7Purity: >97.00%
MKK7-COV-9 is a potent and selective covalent inhibitor of MKK7 and targets a specific protein–protein interaction of MKK7. MKK7-COV-9 blocks primary B cell activation in response to LPS with an EC50 of 4.98 μM.
- GC62404p38α inhibitor 2CAS: 1095003-80-7Purity: >98.50%
p38α inhibitor 2 is a highly potent and selective p38α MAPK inhibitor, with a pIC50 of 9.6.
- GC62448Rineterkib hydrochlorideCAS: 1715025-34-5Purity: >98%
Rineterkib hydrochloride (compound B) is an orally available ERK1 and ERK2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer. Rineterkib hydrochloride can also inhibit RAF.
| Catalog No. | Product Name | CAS No. | Purity | Structure |
|---|---|---|---|---|
| GC60393 | (-)-Zuonin A | 84709-25-1 | >99.50% | |
(-)-Zuonin A (D-Epigalbacin), a naturally occurring lignin, is a potent, selective JNKs inhibitor, with IC50s of 1.7 μM, 2.9 μM and 1.74 μM for JNK1, JNK2 and JNK3, respectively. | ||||
| GC60592 | APS6-45 | 2188236-41-9 | >99.50% | |
APS6-45 is an orally active tumor-calibrated inhibitor (TCI). APS6-45 inhibits RAS/MAPK signaling and exhibits antitumor activity. | ||||
| GC60812 | ASTX029 (ERK1/2 inhibitor 2) | 2095719-92-7 | >99.50% | |
ASTX029 (ERK1/2 inhibitor 2) is a highly effective and selective orally bioavailable extracellular signal-regulated kinase (ERK) 1/2 inhibitor (with an IC 50 of 2.7nM for ERK2). | ||||
| GC60886 | GSK356278 | 720704-34-7 | >99.50% | |
A selective PDE4 inhbitor | ||||
| GC61032 | MCP110 | 521310-51-0 | >98.50% | |
MCP110 is an inhibitor of Ras/Raf-1 interaction. MCP110 blocks the interaction of Ras with Raf. MCP110 disrupts this interaction might can be used for the research of human tumors. | ||||
| GC61454 | GW806742X hydrochloride | - | >98.50% | |
GW806742X hydrochloride, an ATP mimetic and a potent MLKL (Mixed Lineage Kinase Domain-Like protein) inhibitor, binds the MLKL pseudokinase domain with a Kd of 9.3 μM. GW806742X hydrochloride has activity against VEGFR2 (IC50=2 nM). GW806742X hydrochloride retards MLKL membrane translocation and inhibits necroptosis. | ||||
| GC61466 | DMU-212 | 134029-62-2 | >99.50% | |
DMU-212 is a methylated derivative of Resveratrol, with antimitotic, anti-proliferative, antioxidant and apoptosis promoting activities. DMU-212 induces mitotic arrest via induction of apoptosis and activation of ERK1/2 protein. DMU-212 has orally active. | ||||
| GC61485 | Raf inhibitor 2 | 220904-99-4 | >98.00% | |
Raf inhibitor 2 is a potent raf kinase (IC50<1.0 μM) inhibitor, compound 32, extracted from patent EP1003721B1. Raf inhibitor 2 can be used for cancer research. | ||||
| GC61512 | PKA Inhibitor Fragment (6-22) amide TFA | - | >98.00% | |
PKA inhibitor fragment (6-22) amide TFA is a synthetic peptide inhibitor of cAMP-dependent protein kinase A (PKA) with K i =1.7 nM. | ||||
| GC61747 | Sp-cAMPS | 71774-13-5 | >98% | |
Sp-cAMPS, a cAMP analog, is potent activator of cAMP-dependent PKA I and PKA II. | ||||
| GC61765 | (+)-Isomenthone | 1196-31-2 | - | |
(+)-Isomenthone is an isomer of L-Menthone, isolated from Ziziphora clinopodioidesLam. and possesses antioxidant activity. | ||||
| GC61819 | MK2-IN-3 | 724711-21-1 | >98.00% | |
MK2-IN-3 is a potent and selective inhibitor of MAPKAP-K2 (MK-2), with an IC50 of 8.5 nM. | ||||
| GC61849 | PKI 14-22 amide,myristoylated TFA | - | >99.50% | |
PKI 14-22 amide,myristoylated TFA is a potent cAMP-dependent PKA inhibitor. PKI 14-22 amide,myristoylated TFA reduces the IgG-mediated phagocytic response and also inhibits neutrophil adhesion. | ||||
| GC61865 | Cearoin | 52811-37-7 | >98.00% | |
Cearoin increases autophagy and apoptosis through the production of ROS and the activation of ERK. | ||||
| GC61941 | Eudesmin | 526-06-7 | >99.00% | |
Eudesmin ((-)-Eudesmin) impairs adipogenic differentiation via inhibition of S6K1 signaling pathway. | ||||
| GC62146 | XST-14 | 2607143-50-8 | >99.50% | |
XST-14 is a potent, competitive and highly selective ULK1 inhibitor with an IC50 of 26.6 nM. XST-14 induces autophagy inhibition by reducing the phosphorylation of the ULK1 downstream substrate. XST-14 induces apoptosis in hepatocellular carcinoma (HCC) cells and has antitumor effects. | ||||
| GC62206 | PLX-4720-d7 | 1304096-50-1 | >98% | |
PLX-4720-d7 is the deuterium labeled PLX-4720. PLX-4720 is a potent and selective inhibitor of?B-RafV600E?with?an IC50?of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), and 10-fold selectivity for B-RafV600E than wild-type B-Raf. | ||||
| GC62229 | ERK-IN-3 | 2055597-12-9 | >99.00% | |
ERK-IN-3 is a potent and orally active inhibitor of ERK. ERK-IN-3 inhibits ERK1/2 with low single-digit nM IC50 values. ERK-IN-3 can be used for the research of cancers driven by RAS mutations. | ||||
| GC62269 | RRD-251 | 72214-67-6 | >99.50% | |
RRD-251 is an inhibitor of retinoblastoma tumor suppressor protein (Rb)-Raf-1 interaction, with potent anti-proliferative, anti-angiogenic and anti-tumor activities. | ||||
| GC62315 | MKK7-COV-9 | 2283355-59-7 | >97.00% | |
MKK7-COV-9 is a potent and selective covalent inhibitor of MKK7 and targets a specific protein–protein interaction of MKK7. MKK7-COV-9 blocks primary B cell activation in response to LPS with an EC50 of 4.98 μM. | ||||
| GC62404 | p38α inhibitor 2 | 1095003-80-7 | >98.50% | |
p38α inhibitor 2 is a highly potent and selective p38α MAPK inhibitor, with a pIC50 of 9.6. | ||||
| GC62426 | ASK1-IN-2 | 2541792-70-3 | >98.00% | |
ASK1-IN-2 is a potent and orally active inhibitor of apoptosis signal-regulating kinase 1 (ASK1), with an IC50 of 32.8 nM. | ||||
| GC62448 | Rineterkib hydrochloride | 1715025-34-5 | >98% | |
Rineterkib hydrochloride (compound B) is an orally available ERK1 and ERK2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer. Rineterkib hydrochloride can also inhibit RAF. | ||||
| GC62492 | CC-90001 | 1403859-14-2 | >99.50% | |
CC-90001 is a potent, selective and orally active inhibitor of c-Jun N-terminal kinase (JNK). | ||||
